"Dabigatran" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation.
| Descriptor ID |
D000069604
|
| MeSH Number(s) |
D03.383.725.192 D03.633.100.103.280
|
| Concept/Terms |
Dabigatran- Dabigatran
- N-((2-(((4-(aminoiminomethyl)phenyl)amino)methyl)-1-methyl-1H-benzimidazol-5-yl)carbonyl)-N-2-pyridinyl-beta-alanine
|
Below are MeSH descriptors whose meaning is more general than "Dabigatran".
Below are MeSH descriptors whose meaning is more specific than "Dabigatran".
This graph shows the total number of publications written about "Dabigatran" by people in this website by year, and whether "Dabigatran" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 3 | 3 |
| 2012 | 0 | 11 | 11 |
| 2013 | 0 | 9 | 9 |
| 2014 | 0 | 7 | 7 |
| 2015 | 1 | 6 | 7 |
| 2016 | 6 | 4 | 10 |
| 2017 | 9 | 11 | 20 |
| 2018 | 8 | 3 | 11 |
| 2019 | 3 | 3 | 6 |
| 2020 | 2 | 1 | 3 |
| 2021 | 0 | 5 | 5 |
| 2022 | 3 | 3 | 6 |
| 2023 | 0 | 2 | 2 |
| 2024 | 0 | 3 | 3 |
Below are the most recent publications written about "Dabigatran" by people in Profiles.
-
Informing the United States Medicare Drug Price Negotiation for Apixaban and Rivaroxaban: Methodological Considerations for Value Assessments Many Years After Launch. Value Health. 2024 Nov; 27(11):1507-1514.
-
Population Dementia Incidence and Direct Oral Anticoagulant Use in a Representative Population With Atrial Fibrillation. Neurology. 2024 Jul 09; 103(1):e209568.
-
How I treat pediatric venous thromboembolism in the DOAC era. Blood. 2024 02 01; 143(5):389-403.
-
A Real-World Evaluation of Primary Medication Nonadherence in Patients with Nonvalvular Atrial Fibrillation Prescribed Oral Anticoagulants in the United States. Am J Cardiovasc Drugs. 2023 Sep; 23(5):559-572.
-
Identifying treatment heterogeneity in atrial fibrillation using a novel causal machine learning method. Am Heart J. 2023 06; 260:124-140.
-
Proportion of Patients on Warfarin Therapy Who Are Eligible for Conversion to a Direct Oral Anticoagulant in the Setting of COVID-19. Ann Pharmacother. 2023 Aug; 57(8):918-924.
-
Plaque Progression Differences Between Apixaban and Rivaroxaban in Patients With Atrial Fibrillation Measured With Cardiac Computed Tomography and Plaque Quantification. Am J Ther. 2023 Jul-Aug 01; 30(4):e313-e320.
-
Risk of stroke/systemic embolism, major bleeding, and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States medicare population: updated analysis. Curr Med Res Opin. 2022 12; 38(12):2131-2140.
-
Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study. Stroke. 2022 03; 53(3):728-738.
-
Direct oral anticoagulants for use in paediatrics. Lancet Child Adolesc Health. 2022 03; 6(3):207-214.